– USA, WA – Novo Integrated Sciences, Inc. (OTC: NVOS), a provider of multi-dimensional primary healthcare services and products in Canada and the U.S., today announced the appointment of Michael Pope, Robert Oliva, and Alex Flesias to its Board as Independent Directors, increasing the size of the Board from 4 to 7.
These three individuals have also been appointed to serve on the newly formed Audit Committee, with Mr. Pope being the Committee Chairman.
“We are extremely pleased to welcome Michael, Rob and Alex as new independent directors to the Novo Integrated Sciences Board. The addition of top talent and highly accomplished leaders to our Board and Audit Committee will provide valuable perspectives and experience as we continue to execute our strategy, drive growth and work to build long-term shareholder value for our Company.” said CEO and Chairman, Robert Mattacchione.
About Michael Pope
Michael Pope serves as the CEO and Chairman at Boxlight Corporation (Nasdaq: BOXL), a global provider of interactive technology solutions, where he has been an executive since July 2015 and director since September 2014. Mr. Pope has led Boxlight through nine acquisitions from 2016 to 2020, a Nasdaq IPO in November 2017, and over $100 million in debt and equity fundraising. He previously served as Managing Director at Vert Capital, private equity and advisory firm from October 2011 to October 2016, managing portfolio holdings in the education, consumer products, technology, and digital media sectors.
Before joining Vert Capital, from May 2008 to October 2011, Mr. Pope was CFO and COO for the Taylor Family in Salt Lake City, managing family investment holdings in consumer products, professional services, real estate, and education. Mr. Pope also held positions including senior SEC reporting at Omniture and Assurance Associate at Grant Thornton.
He holds an active CPA license and serves on the boards of various organizations. Mr. Pope earned his undergraduate and graduate degrees in accounting from Brigham Young University with academic honors. Our Board believes Mr. Pope’s broad and extensive finance and operations experience uniquely position him to provide a wide array of insight and knowledge as the Company pursues its next phase of growth and expansion.
About Rob Oliva
Rob Oliva is the owner of Toronto-based Venture Metal Works, a leading mid-market enterprise which specializes in architectural and structural steel design, fabrication, and manufacturing for the construction industry throughout Canada. Before founding Venture Metal Works in 2011, for 28 years Mr. Oliva worked for, and ultimately became the owner of, Tor Steel Company Limited, which provided architectural and structural steel products for the Canadian based construction industry. For over 39 years, Mr. Oliva has developed proven expertise in delivering system and operational efficiency while managing aggressive, yet sustainable growth. As a successful business owner, he brings the Company a wealth of knowledge in areas related to implementing efficient operational strategy, developing system processes, supply-chain management, and sales. Mr. Oliva’s proven business development success provides the Company with the ability to determine the optimal balance of both present activity and future vision and its direct impact on the Company’s strategic direction and priorities.
About Alex Flesias
Alex Flesias, B.A., LLB has been a partner at Hammond Flesias Law Firm in Toronto, Canada since 2007. Mr. Flesias manages a general commercial litigation practice with a strong focus on construction and real estate related matters. Mr. Flesias has extensive experience litigating complex disputes involving financial institutions, as well as landlord-tenant matters. In 1997, Mr. Flesias graduated with an Honours Bachelor of Arts Degree in Political Science and History from the University of Toronto, followed by earning his Master of Arts degree in Political Science at York University in 1998. Mr. Flesias obtained his LLB from Osgoode Hall Law School in 2000. As a lawyer with vast exposure to the business world, Alex provides the Company with a unique diversity of thought and background integral to making well-informed decisions and judgments.
About Novo Integrated Sciences, Inc.
Novo Integrated Sciences, Inc. is a U.S. based corporation which owns Canadian and U.S. subsidiaries that deliver or intend to deliver, multidisciplinary primary health care related services and products through the integration of medical technology, advanced therapeutics, and rehabilitative science.
Currently, the Company’s revenue is generated solely through its wholly-owned Canadian subsidiary, Novo Healthnet Limited, which provides services and products through both clinic and eldercare related operations.
NHL’s team of multidisciplinary primary health care clinicians and practitioners provide assessment, diagnosis, treatment, pain management, rehabilitation, education, and primary prevention for a wide array of orthopedic, musculoskeletal, sports injury, and neurological conditions across various demographics including pediatric, adult, and geriatric populations through NHL’s 16 corporate-owned clinics, a contracted network of 103 affiliate clinics, and 218 eldercare related long-term care homes, retirement homes, and community-based locations in Canada.
Additionally, we continue to expand our patient care philosophy of maintaining an on-going continuous connection with our patient community, beyond the traditional confines of brick-and-mortar facilities, by extending oversight of patient diagnosis, care, and monitoring, directly through various Medical Technology Platforms, either in-use or under development.
For more information: https://novointegrated.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
